A provider briefing on Asthmanefrin availability in 2026. Key facts on supply status, prescribing implications, alternatives, and patient resources.
Patients are increasingly asking their healthcare providers about Asthmanefrin (Racepinephrine Hydrochloride 2.25%), the over-the-counter bronchodilator marketed by Nephron Pharmaceuticals. Some patients rely on it because they lack insurance or regular access to a prescriber. Others have been using it for years as a convenient, no-prescription-needed rescue option.
This article provides a clinical overview of the current Asthmanefrin supply situation, its implications for your practice, and the tools available to help patients who are struggling to find this product.
Asthmanefrin is an OTC adrenergic bronchodilator containing Racepinephrine Hydrochloride 2.25% (equivalent to approximately 1% epinephrine) in 0.5 mL single-use vials. It is administered via the EZ Breathe Atomizer, a hand-held bulb nebulizer included with the Starter Kit.
Key clinical details:
It is important to note that Asthmanefrin is intended for mild, intermittent symptoms only. Patients using it more than twice per week or requiring more than 9 inhalations in 24 hours for 3+ days per week may have undertreated persistent asthma requiring step-up therapy.
Asthmanefrin was launched in August 2012 by Nephron Pharmaceuticals as an OTC alternative to the discontinued Primatene Mist CFC inhaler. Key timeline points:
While Asthmanefrin does not require a prescription, its availability issues have clinical implications that providers should be aware of:
Patients who rely exclusively on OTC products like Asthmanefrin for asthma management may not be receiving guideline-concordant care. If a patient reports difficulty finding Asthmanefrin, it's an opportunity to:
Racepinephrine's non-selective mechanism means it stimulates alpha-1, beta-1, and beta-2 receptors. Compared to Albuterol (selective beta-2), this carries greater cardiovascular risk, including:
For patients with comorbid cardiovascular disease, hypertension, diabetes, thyroid disorders, or those taking MAO inhibitors, Asthmanefrin is not an appropriate choice.
The most critical interaction is with MAO inhibitors — Asthmanefrin is contraindicated within 14 days of MAO inhibitor use. Other interactions of clinical concern include:
For a comprehensive reference, see our article on Asthmanefrin drug interactions.
As of early 2026:
One reason patients gravitate toward OTC products is cost and access. Important context for providers:
The cost advantage of OTC has narrowed significantly in 2026. Patients who previously avoided the healthcare system for cost reasons may now find prescription options more affordable.
If your patients are struggling to find Asthmanefrin or need help navigating their options:
The OTC asthma treatment landscape may continue to evolve. Key trends to watch:
Asthmanefrin's availability challenges present an opportunity for providers to engage patients about their asthma management. For many patients using OTC epinephrine products, a proper asthma evaluation and a prescription for a selective beta-2 agonist would represent a meaningful improvement in their care.
When patients ask about Asthmanefrin, consider it a conversation starter — not just about finding the product, but about whether their asthma is being optimally managed.
For more clinical resources, visit Medfinder for Providers. For patient-facing information, share our guides on what Asthmanefrin is and alternatives to Asthmanefrin.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
